- Home
- RAYA vs ESLA Comparison
RAYA vs ESLA Comparison
Compare RAYA & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAYA
- ESLA
- Stock Information
- Founded
- RAYA 2019
- ESLA 2021
- Country
- RAYA China
- ESLA United States
- Employees
- RAYA N/A
- ESLA N/A
- Industry
- RAYA Metal Fabrications
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAYA Consumer Discretionary
- ESLA Health Care
- Exchange
- RAYA Nasdaq
- ESLA Nasdaq
- Market Cap
- RAYA 34.2M
- ESLA 32.1M
- IPO Year
- RAYA 2022
- ESLA N/A
- Fundamental
- Price
- RAYA $1.32
- ESLA $1.16
- Analyst Decision
- RAYA
- ESLA Strong Buy
- Analyst Count
- RAYA 0
- ESLA 1
- Target Price
- RAYA N/A
- ESLA $16.00
- AVG Volume (30 Days)
- RAYA 22.2K
- ESLA 69.3K
- Earning Date
- RAYA 01-01-0001
- ESLA 05-20-2025
- Dividend Yield
- RAYA N/A
- ESLA N/A
- EPS Growth
- RAYA N/A
- ESLA N/A
- EPS
- RAYA N/A
- ESLA N/A
- Revenue
- RAYA $30,300,360.00
- ESLA N/A
- Revenue This Year
- RAYA $20.95
- ESLA N/A
- Revenue Next Year
- RAYA N/A
- ESLA N/A
- P/E Ratio
- RAYA N/A
- ESLA N/A
- Revenue Growth
- RAYA 49.10
- ESLA N/A
- 52 Week Low
- RAYA $0.56
- ESLA $0.63
- 52 Week High
- RAYA $1.90
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- RAYA 44.13
- ESLA 63.32
- Support Level
- RAYA $1.23
- ESLA $1.02
- Resistance Level
- RAYA $1.59
- ESLA $1.22
- Average True Range (ATR)
- RAYA 0.15
- ESLA 0.10
- MACD
- RAYA -0.04
- ESLA 0.02
- Stochastic Oscillator
- RAYA 14.75
- ESLA 78.57
About RAYA Erayak Power Solution Group Inc.
Erayak Power Solution Group Inc engages in manufacturing, research and development, and wholesale and retail of power solution products. Its product portfolio includes sine wave and off-grid inverters, inverter and gasoline generators, battery, and smart chargers, and custom-designed products. It derives the majority revenue from three products namely inverters, chargers, and gasoline generators. The company geographically operates in China, Australia, Poland, U.K., and Germany. It derives maximum revenue from China.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.